<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734162</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-174-0115</org_study_id>
    <nct_id>NCT00734162</nct_id>
  </id_info>
  <brief_title>Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection</brief_title>
  <official_title>A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents With Chronic Hepatitis B Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to evaluate the effectiveness, safety, and tolerability
      of tenofovir disoproxil fumarate (TDF) in adolescents (aged 12-17 years) with chronic
      hepatitis B virus (HBV) infection.

      The optimal treatment for adolescents with chronic HBV infection is currently unknown.
      Treatment with interferon alfa, lamivudine, and adefovir dipivoxil in pediatric populations
      has been shown to be less than optimal. Further, the safety and efficacy of entecavir and
      telbivudine have not been established in patients &lt; 16 years of age. A study evaluating TDF
      in adolescents (ages 12-17) was needed to assess the safety and efficacy of this agent in the
      treatment of chronic hepatitis B in this patient population. In addition, the study will help
      to further elucidate the pharmacokinetic (PK) and resistance profiles of TDF. Through their
      participation, study participants will help generate critical new information to help guide
      the most optimal treatment of chronic HBV infection in adolescents.

      This is a randomized, double-blind study to evaluate the antiviral efficacy, safety, and
      tolerability of TDF versus placebo in adolescents with chronic HBV infection. TDF
      treatment-naive participants were randomized in a 1:1 ratio to TDF or placebo. After 72 weeks
      of blinded treatment, participants were to switch to open-label TDF for an additional 2.5
      years of treatment, provided that no safety concerns are identified by the Independent Data
      Monitoring Committee monitoring the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With HBV DNA &lt; 400 Copies/mL at Week 72</measure>
    <time_frame>Week 72</time_frame>
    <description>The percentage of participants with HBV DNA &lt; 400 copies/mL at Week 72 was summarized by treatment and age group (grouped by baseline age for analysis), using the missing = failure (M = F) analysis with the double-blind efficacy evaluation (DBEE) algorithm.
In the M = F analysis method, all missing data were considered as failure to meet the outcome measure threshold. This method was combined with the DBEE algorithm, which included all available data for the double-blind period, and any data for the open-label period were not included; data generated during treatment-free follow-up from subjects who achieved HBsAg loss and entered treatment-free follow-up during double-blind treatment period were included.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least a 6% Decrease From Baseline in Bone Mineral Density (BMD) of the Spine at Week 72</measure>
    <time_frame>Baseline to Week 72</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).
In contrast with what was previously reported in the interim results posting, 1 participant met the primary safety endpoint of at least a 6% decrease from baseline in spine BMD at Week 72, based on the final BMD data analysis. The apparent discrepancy was due to the correction factor applied to the subject-specific BMD calculations performed at the time of the Interim Week 72 clinical study report that could not take into account the actual Week 72 phantom data (ie, calibration test used in longitudinal clinical trials to monitor and adjust for shifts in the dual-energy x-ray absorptiometry (DXA) scanner calibration over time), which were not provided by the site at that time. The correction factor applied to the final analysis has been properly based on all phantom data through the end of Week 72, as well as through the end of Week 192.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HBV DNA &lt; 400 Copies/mL at Weeks 48, 96, 144, and 192</measure>
    <time_frame>Weeks 48, 96, 144, and 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Weeks 48, 72, 96, 144, and 192</measure>
    <time_frame>Weeks 48, 72, 96, 144, and 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HBV DNA &lt; 400 Copies/mL and Normal ALT at Weeks 48, 72, 96, 144, and 192</measure>
    <time_frame>Weeks 48, 72, 96, 144, and 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HBV DNA &lt; 169 Copies/mL at Weeks 48, 72, 96, 144, and 192</measure>
    <time_frame>Weeks 48, 72, 96, 144, and 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48, 72, 96, 144, and 192</measure>
    <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HBsAg Seroconversion at Weeks 48, 72, 96, 144, and 192</measure>
    <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
    <description>HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least a 6% Decrease From Baseline in Spine BMD at Weeks 48, 96, 144, and 192</measure>
    <time_frame>Baseline; Weeks 48, 96, 144, and 192</time_frame>
    <description>The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least a 6% Decrease From Baseline in Whole Body BMD at Weeks 48, 72, 96, 144, and 192</measure>
    <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
    <description>The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Spine Bone Mineral Density (BMD) at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Spine BMD at Week 72</measure>
    <time_frame>Baseline; Week 72</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Spine BMD at Week 96</measure>
    <time_frame>Baseline; Week 96</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Spine BMD at Week 144</measure>
    <time_frame>Baseline; Week 144</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Spine BMD at Week 192</measure>
    <time_frame>Baseline; Week 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Whole Body BMD at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Whole Body BMD at Week 72</measure>
    <time_frame>Baseline; Week 72</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Whole Body BMD at Week 96</measure>
    <time_frame>Baseline; Week 96</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Whole Body BMD at Week 144</measure>
    <time_frame>Baseline; Week 144</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Whole Body BMD at Week 192</measure>
    <time_frame>Baseline; Week 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Z-score for Spine BMD at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
    <description>To assess any effect of treatment on growth, Z-scores were used to express the deviation from a reference population for lumbar spine BMD. A Z-score of 0 indicated that a subject was typical of the population for their age, ethnicity, and gender. A negative Z-score indicated that the subject's recorded value was lower than typical for their age, ethnicity, and gender. A positive Z-score indicates that the subject's recorded value was higher than typical for their age, ethnicity, and gender. Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Z-score for Spine BMD at Week 72</measure>
    <time_frame>Baseline; Week 72</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Z-score for Spine BMD at Week 96</measure>
    <time_frame>Baseline; Week 96</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Z-score for Spine BMD at Week 144</measure>
    <time_frame>Baseline; Week 144</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Z-score for Spine BMD at Week 192</measure>
    <time_frame>Baseline; Week 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Z-score for Whole Body BMD at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Z-score for Whole Body BMD at Week 72</measure>
    <time_frame>Baseline; Week 72</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Z-score for Whole Body BMD at Week 96</measure>
    <time_frame>Baseline; Week 96</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Z-score for Whole Body BMD at Week 144</measure>
    <time_frame>Baseline; Week 144</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Z-score for Whole Body BMD at Week 192</measure>
    <time_frame>Baseline; Week 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Changes in Drug-Resistant Mutations During the Study</measure>
    <time_frame>Baseline through Week 192</time_frame>
    <description>The number of participants with changes in drug-resistant mutations during the study was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Loss at Weeks 48, 72, 96, 144, and 192</measure>
    <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Seroconversion at Weeks 48, 72, 96, 144, and 192</measure>
    <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were HBeAg-Positive at Baseline Who Had HBV DNA &lt; 400 Copies/mL, Normal ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192</measure>
    <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Abnormal ALT at Baseline Who Had Normalized ALT at Weeks 48, 72, 96, 144, and 192</measure>
    <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Abnormal ALT at Baseline Who Had HBV DNA &lt; 400 Copies/mL and Normalized ALT at Weeks 48, 72, 96, 144, and 192</measure>
    <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were HBeAg-Positive With Abnormal ALT at Baseline Who Had HBV DNA &lt; 400 Copies/mL, Normalized ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192</measure>
    <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
    <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Hepatitis B Virus (HBV)</condition>
  <arm_group>
    <arm_group_label>Tenofovir disoproxil fumarate (TDF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate (TDF)</intervention_name>
    <description>TDF administered as a 300-mg tablet once daily</description>
    <arm_group_label>Tenofovir disoproxil fumarate (TDF)</arm_group_label>
    <other_name>Viread®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>TDF placebo tablet once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female, 12 through 17 years of age, inclusive (consent of parent/legal
             guardian required)

          -  Documented chronic HBV infection

          -  HBeAg positive or HBeAg negative

          -  Weight &gt; 35 kg

          -  Able to swallow oral tablets

          -  HBV DNA &gt; 100,000 copies/mL (polymerase chain reaction (PCR) method)

          -  Alanine aminotransferase (ALT) &gt; 2 × upper limit of normal (ULN) at screening, OR any
             history of ALT &gt; 2 × ULN over the past 24 months

          -  Willing and able to provide written informed consent/assent (child and parent/legal
             guardian)

          -  Negative serum pregnancy test (for postmenarchal females only)

          -  Estimated glomerular filtration rate (creatinine clearance [using the Schwartz
             formula]) &gt; 80 mL/min/1.73m^2

          -  Adequate hematologic function (absolute neutrophil count ≥ 1,500/mm^3; hemoglobin ≥
             10.0 g/dL)

          -  No prior TDF therapy (participants may have received prior interferon or oral anti-HBV
             nucleoside/nucleotide therapy; participants must have discontinued interferon therapy
             ≥ 6 months prior to screening; participants experienced on anti-HBV
             nucleoside/nucleotide therapy must have discontinued therapy ≥ 16 weeks prior to
             screening to avoid flare if randomized to the placebo arm)

        Exclusion Criteria

          -  Pregnant women, women who are breast feeding or who believe they may wish to become
             pregnant during the course of the study

          -  Males and females of reproductive potential who are not willing to use an effective
             method of contraception during the study

          -  Decompensated liver disease

          -  Receipt of interferon (pegylated or not) therapy within 6 months of the Screening
             Visit

          -  Receipt of anti-HBV nucleoside/nucleotide therapy within 16 weeks of the Screening
             Visit

          -  Alpha fetoprotein &gt; 50 ng/mL

          -  Evidence of hepatocellular carcinoma (HCC)

          -  Coinfection with HIV, hepatitis C virus (HCV), or hepatitis D virus (HDV)

          -  History of significant renal disease (eg, nephrotic syndrome, renal dysgenesis,
             polycystic kidney disease, congenital nephrosis, acute tubular necrosis, other renal
             disease)

          -  History of significant bone disease (eg, osteomalacia, chronic osteomyelitis,
             osteogenesis imperfecta, osteochondroses, multiple bone fractures)

          -  Significant cardiovascular, pulmonary, or neurological disease

          -  Evidence of a gastrointestinal malabsorption syndrome that may interfere with
             absorption of orally administered medications

          -  History of solid organ or bone marrow transplantation

          -  Ongoing therapy with nephrotoxic agents, competitors of renal excretion, systemic
             chemotherapeutic agents, systemic corticosteroids, interleukin-2 (IL-2), or other
             immunomodulating or investigational agents

          -  Known hypersensitivity to the study drugs, the metabolites or formulation excipients

          -  Any other condition (including alcohol or substance abuse) or prior therapy that, in
             the opinion of the Investigator, would make the participants unsuitable for the study
             or unable to comply with dosing requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedetta Massetto, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital &amp; Research Center at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital &amp; Regional Medical Center, d/b/a Seattle Children's Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Sveti Georgi</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Gastroenterology, Specialized Hospital for Active Treatment of Pediatric Diseases, Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Femmes Meres Enfants</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Dzieciecy Szpital Kliniczny Akademii Medycznej w Bialymstoku</name>
      <address>
        <city>Białystok</city>
        <zip>15-274</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital im Bieganskiego</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Obserwacyjno-Zakazny im. T. Browicza</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawla II</name>
      <address>
        <city>Kraków</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny im. Karola Johschera</name>
      <address>
        <city>Poznan</city>
        <zip>60-572</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Zespol Opieki Zdrowotnej nad Matka i Dzieckiem</name>
      <address>
        <city>Poznań</city>
        <zip>61-734</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zakazny</name>
      <address>
        <city>Warszawa</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1</name>
      <address>
        <city>Wrocław</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundeni Clinical Institute</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Infectious Diseases</name>
      <address>
        <city>Bucharest</city>
        <zip>21105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cluj Childrens Emergency Hospital</name>
      <address>
        <city>Napaco</city>
        <zip>400217</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Univ y Politecnico La Fe de Valencia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario De Getafe</name>
      <address>
        <city>Madrid</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi Hastanesi</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <results_reference>
    <citation>Murray KF, Szenborn L, Wysocki J, Rossi S, Corsa AC, Dinh P, McHutchison J, Pang PS, Luminos LM, Pawlowska M, Mizerski J. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology. 2012 Dec;56(6):2018-26. doi: 10.1002/hep.25818. Epub 2012 Aug 27.</citation>
    <PMID>22544804</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <results_first_submitted>October 8, 2012</results_first_submitted>
  <results_first_submitted_qc>October 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 7, 2012</results_first_posted>
  <disposition_first_submitted>April 16, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 16, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 18, 2012</disposition_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tenofovir</keyword>
  <keyword>adolescents</keyword>
  <keyword>chronic hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 3 sites in the United States, 8 sites in Poland, 3 sites in Romania, 2 sites in Bulgaria, 2 sites in France, 2 sites in Spain, and 1 site in Turkey. The first participant was screened on 03 December 2008. The last study visit occurred on 02 December 2015.</recruitment_details>
      <pre_assignment_details>149 participants were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TDF 12-14 Years</title>
          <description>Tenofovir disoproxil fumarate (TDF) 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
        </group>
        <group group_id="P2">
          <title>TDF 15-17 Years</title>
          <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
        </group>
        <group group_id="P3">
          <title>Placebo 12-14 Years</title>
          <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
        </group>
        <group group_id="P4">
          <title>Placebo 15-17 Years</title>
          <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Phase (Through Week 72)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Investigator's Discretion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Per protocol ALT elevation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="39">2 participants switched to open-label treatment before completing double-blind period (elevated ALT)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Safety, Tolerability or Efficacy Reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Meet Entrance Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TDF 12-14 Years</title>
          <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
        </group>
        <group group_id="B2">
          <title>TDF 15-17 Years</title>
          <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
        </group>
        <group group_id="B3">
          <title>Placebo 12-14 Years</title>
          <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
        </group>
        <group group_id="B4">
          <title>Placebo 15-17 Years</title>
          <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="41"/>
            <count group_id="B5" value="106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.3" spread="0.82"/>
                    <measurement group_id="B2" value="16.1" spread="0.75"/>
                    <measurement group_id="B3" value="13.2" spread="0.69"/>
                    <measurement group_id="B4" value="15.9" spread="0.82"/>
                    <measurement group_id="B5" value="15.4" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine aminotransferase (ALT) level at baseline</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77" spread="54.8"/>
                    <measurement group_id="B2" value="106" spread="116.4"/>
                    <measurement group_id="B3" value="101" spread="95.4"/>
                    <measurement group_id="B4" value="101" spread="89.5"/>
                    <measurement group_id="B5" value="101" spread="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ALT normal at baseline</title>
          <description>The upper limit of normal (ULN) was 43 U/L for males and 34 U/L for females.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBV Genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Genotype A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis B e Antigen (HBeAg) status at baseline</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBV DNA level at baseline</title>
          <units>Log_10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.26" spread="1.455"/>
                    <measurement group_id="B2" value="7.95" spread="1.421"/>
                    <measurement group_id="B3" value="8.61" spread="1.166"/>
                    <measurement group_id="B4" value="8.12" spread="1.451"/>
                    <measurement group_id="B5" value="8.13" spread="1.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With HBV DNA &lt; 400 Copies/mL at Week 72</title>
        <description>The percentage of participants with HBV DNA &lt; 400 copies/mL at Week 72 was summarized by treatment and age group (grouped by baseline age for analysis), using the missing = failure (M = F) analysis with the double-blind efficacy evaluation (DBEE) algorithm.
In the M = F analysis method, all missing data were considered as failure to meet the outcome measure threshold. This method was combined with the DBEE algorithm, which included all available data for the double-blind period, and any data for the open-label period were not included; data generated during treatment-free follow-up from subjects who achieved HBsAg loss and entered treatment-free follow-up during double-blind treatment period were included.</description>
        <time_frame>Week 72</time_frame>
        <population>Full Analysis Set: participants who were randomized and received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBV DNA &lt; 400 Copies/mL at Week 72</title>
          <description>The percentage of participants with HBV DNA &lt; 400 copies/mL at Week 72 was summarized by treatment and age group (grouped by baseline age for analysis), using the missing = failure (M = F) analysis with the double-blind efficacy evaluation (DBEE) algorithm.
In the M = F analysis method, all missing data were considered as failure to meet the outcome measure threshold. This method was combined with the DBEE algorithm, which included all available data for the double-blind period, and any data for the open-label period were not included; data generated during treatment-free follow-up from subjects who achieved HBsAg loss and entered treatment-free follow-up during double-blind treatment period were included.</description>
          <population>Full Analysis Set: participants who were randomized and received at least one dose of study drug</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="88.1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="88.5"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis is the difference between treatment groups in the proportion of participants who met the outcome measure criterion, controlling for randomization age group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>A p-value of &lt; 0.05 was considered statistically significant.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least a 6% Decrease From Baseline in Bone Mineral Density (BMD) of the Spine at Week 72</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).
In contrast with what was previously reported in the interim results posting, 1 participant met the primary safety endpoint of at least a 6% decrease from baseline in spine BMD at Week 72, based on the final BMD data analysis. The apparent discrepancy was due to the correction factor applied to the subject-specific BMD calculations performed at the time of the Interim Week 72 clinical study report that could not take into account the actual Week 72 phantom data (ie, calibration test used in longitudinal clinical trials to monitor and adjust for shifts in the dual-energy x-ray absorptiometry (DXA) scanner calibration over time), which were not provided by the site at that time. The correction factor applied to the final analysis has been properly based on all phantom data through the end of Week 72, as well as through the end of Week 192.</description>
        <time_frame>Baseline to Week 72</time_frame>
        <population>Safety Analysis Set: participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 6% Decrease From Baseline in Bone Mineral Density (BMD) of the Spine at Week 72</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).
In contrast with what was previously reported in the interim results posting, 1 participant met the primary safety endpoint of at least a 6% decrease from baseline in spine BMD at Week 72, based on the final BMD data analysis. The apparent discrepancy was due to the correction factor applied to the subject-specific BMD calculations performed at the time of the Interim Week 72 clinical study report that could not take into account the actual Week 72 phantom data (ie, calibration test used in longitudinal clinical trials to monitor and adjust for shifts in the dual-energy x-ray absorptiometry (DXA) scanner calibration over time), which were not provided by the site at that time. The correction factor applied to the final analysis has been properly based on all phantom data through the end of Week 72, as well as through the end of Week 192.</description>
          <population>Safety Analysis Set: participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1.9"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HBV DNA &lt; 400 Copies/mL at Weeks 48, 96, 144, and 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
        <time_frame>Weeks 48, 96, 144, and 192</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBV DNA &lt; 400 Copies/mL at Weeks 48, 96, 144, and 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="86.5"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="88.1"/>
                    <measurement group_id="O3" value="53.8"/>
                    <measurement group_id="O4" value="68.3"/>
                    <measurement group_id="O5" value="88.5"/>
                    <measurement group_id="O6" value="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.5"/>
                    <measurement group_id="O3" value="69.2"/>
                    <measurement group_id="O4" value="85.4"/>
                    <measurement group_id="O5" value="92.3"/>
                    <measurement group_id="O6" value="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="76.9"/>
                    <measurement group_id="O4" value="73.2"/>
                    <measurement group_id="O5" value="86.5"/>
                    <measurement group_id="O6" value="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Weeks 48, 72, 96, 144, and 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
        <time_frame>Weeks 48, 72, 96, 144, and 192</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Weeks 48, 72, 96, 144, and 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0"/>
                    <measurement group_id="O2" value="76.2"/>
                    <measurement group_id="O3" value="30.8"/>
                    <measurement group_id="O4" value="26.8"/>
                    <measurement group_id="O5" value="75.0"/>
                    <measurement group_id="O6" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="76.2"/>
                    <measurement group_id="O3" value="30.8"/>
                    <measurement group_id="O4" value="41.5"/>
                    <measurement group_id="O5" value="76.9"/>
                    <measurement group_id="O6" value="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="76.2"/>
                    <measurement group_id="O3" value="69.2"/>
                    <measurement group_id="O4" value="65.9"/>
                    <measurement group_id="O5" value="76.9"/>
                    <measurement group_id="O6" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="69.2"/>
                    <measurement group_id="O4" value="75.6"/>
                    <measurement group_id="O5" value="69.2"/>
                    <measurement group_id="O6" value="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="84.6"/>
                    <measurement group_id="O4" value="75.6"/>
                    <measurement group_id="O5" value="73.1"/>
                    <measurement group_id="O6" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HBV DNA &lt; 400 Copies/mL and Normal ALT at Weeks 48, 72, 96, 144, and 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
        <time_frame>Weeks 48, 72, 96, 144, and 192</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBV DNA &lt; 400 Copies/mL and Normal ALT at Weeks 48, 72, 96, 144, and 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0"/>
                    <measurement group_id="O2" value="69.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="69.2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="69.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="71.2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="73.8"/>
                    <measurement group_id="O3" value="46.2"/>
                    <measurement group_id="O4" value="51.2"/>
                    <measurement group_id="O5" value="75.0"/>
                    <measurement group_id="O6" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="69.0"/>
                    <measurement group_id="O3" value="53.8"/>
                    <measurement group_id="O4" value="68.3"/>
                    <measurement group_id="O5" value="67.3"/>
                    <measurement group_id="O6" value="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="64.3"/>
                    <measurement group_id="O3" value="69.2"/>
                    <measurement group_id="O4" value="63.4"/>
                    <measurement group_id="O5" value="67.3"/>
                    <measurement group_id="O6" value="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HBV DNA &lt; 169 Copies/mL at Weeks 48, 72, 96, 144, and 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
        <time_frame>Weeks 48, 72, 96, 144, and 192</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBV DNA &lt; 169 Copies/mL at Weeks 48, 72, 96, 144, and 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="81.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="80.8"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="83.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="84.6"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="88.1"/>
                    <measurement group_id="O3" value="53.8"/>
                    <measurement group_id="O4" value="63.4"/>
                    <measurement group_id="O5" value="88.5"/>
                    <measurement group_id="O6" value="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="88.1"/>
                    <measurement group_id="O3" value="69.2"/>
                    <measurement group_id="O4" value="82.9"/>
                    <measurement group_id="O5" value="88.5"/>
                    <measurement group_id="O6" value="79.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="83.3"/>
                    <measurement group_id="O3" value="76.9"/>
                    <measurement group_id="O4" value="73.2"/>
                    <measurement group_id="O5" value="84.6"/>
                    <measurement group_id="O6" value="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48, 72, 96, 144, and 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F.</description>
        <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48, 72, 96, 144, and 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1.9"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1.9"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1.9"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1.9"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HBsAg Seroconversion at Weeks 48, 72, 96, 144, and 192</title>
        <description>HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F.</description>
        <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBsAg Seroconversion at Weeks 48, 72, 96, 144, and 192</title>
          <description>HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1.9"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1.9"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1.9"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least a 6% Decrease From Baseline in Spine BMD at Weeks 48, 96, 144, and 192</title>
        <description>The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Weeks 48, 96, 144, and 192</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 6% Decrease From Baseline in Spine BMD at Weeks 48, 96, 144, and 192</title>
          <description>The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Safety Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1.9"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1.9"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.8"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4.9"/>
                    <measurement group_id="O5" value="3.8"/>
                    <measurement group_id="O6" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least a 6% Decrease From Baseline in Whole Body BMD at Weeks 48, 72, 96, 144, and 192</title>
        <description>The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 6% Decrease From Baseline in Whole Body BMD at Weeks 48, 72, 96, 144, and 192</title>
          <description>The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Safety Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Spine Bone Mineral Density (BMD) at Week 48</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 48</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Spine Bone Mineral Density (BMD) at Week 48</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.234" spread="3.4782"/>
                    <measurement group_id="O2" value="2.114" spread="3.6023"/>
                    <measurement group_id="O3" value="9.038" spread="6.6575"/>
                    <measurement group_id="O4" value="4.435" spread="4.9091"/>
                    <measurement group_id="O5" value="3.510" spread="4.5507"/>
                    <measurement group_id="O6" value="5.562" spread="5.6772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Spine BMD at Week 72</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 72</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Spine BMD at Week 72</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.516" spread="3.8818"/>
                    <measurement group_id="O2" value="3.589" spread="4.5633"/>
                    <measurement group_id="O3" value="14.131" spread="9.9563"/>
                    <measurement group_id="O4" value="6.117" spread="6.0624"/>
                    <measurement group_id="O5" value="5.144" spread="5.4291"/>
                    <measurement group_id="O6" value="8.080" spread="7.8996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Spine BMD at Week 96</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 96</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Spine BMD at Week 96</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.811" spread="4.6712"/>
                    <measurement group_id="O2" value="4.196" spread="4.8021"/>
                    <measurement group_id="O3" value="16.687" spread="10.4359"/>
                    <measurement group_id="O4" value="4.272" spread="7.0463"/>
                    <measurement group_id="O5" value="6.119" spread="6.1200"/>
                    <measurement group_id="O6" value="7.003" spread="9.3658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Spine BMD at Week 144</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 144</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Spine BMD at Week 144</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.224" spread="8.7594"/>
                    <measurement group_id="O2" value="5.289" spread="5.8084"/>
                    <measurement group_id="O3" value="21.346" spread="13.4709"/>
                    <measurement group_id="O4" value="6.144" spread="8.3286"/>
                    <measurement group_id="O5" value="8.133" spread="8.5611"/>
                    <measurement group_id="O6" value="9.311" spread="11.3262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Spine BMD at Week 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 192</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Spine BMD at Week 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.933" spread="8.5166"/>
                    <measurement group_id="O2" value="6.673" spread="7.2870"/>
                    <measurement group_id="O3" value="25.036" spread="14.2346"/>
                    <measurement group_id="O4" value="6.867" spread="9.3736"/>
                    <measurement group_id="O5" value="10.050" spread="10.1637"/>
                    <measurement group_id="O6" value="11.212" spread="13.1459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Whole Body BMD at Week 48</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 48</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Whole Body BMD at Week 48</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.123" spread="3.8309"/>
                    <measurement group_id="O2" value="1.339" spread="1.9324"/>
                    <measurement group_id="O3" value="5.470" spread="3.4958"/>
                    <measurement group_id="O4" value="3.236" spread="2.8573"/>
                    <measurement group_id="O5" value="2.048" spread="2.7830"/>
                    <measurement group_id="O6" value="3.817" spread="3.1576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Whole Body BMD at Week 72</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 72</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Whole Body BMD at Week 72</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.282" spread="3.9156"/>
                    <measurement group_id="O2" value="2.141" spread="2.6284"/>
                    <measurement group_id="O3" value="8.480" spread="4.4770"/>
                    <measurement group_id="O4" value="4.335" spread="3.4073"/>
                    <measurement group_id="O5" value="3.067" spread="3.4819"/>
                    <measurement group_id="O6" value="5.391" spread="4.0902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Whole Body BMD at Week 96</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 96</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Whole Body BMD at Week 96</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.034" spread="3.4973"/>
                    <measurement group_id="O2" value="3.023" spread="3.2063"/>
                    <measurement group_id="O3" value="10.056" spread="5.4296"/>
                    <measurement group_id="O4" value="4.291" spread="4.3195"/>
                    <measurement group_id="O5" value="3.943" spread="3.7730"/>
                    <measurement group_id="O6" value="5.675" spread="5.1858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Whole Body BMD at Week 144</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 144</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Whole Body BMD at Week 144</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.940" spread="4.8819"/>
                    <measurement group_id="O2" value="3.529" spread="3.1734"/>
                    <measurement group_id="O3" value="12.638" spread="5.9973"/>
                    <measurement group_id="O4" value="4.730" spread="5.2213"/>
                    <measurement group_id="O5" value="4.949" spread="4.5753"/>
                    <measurement group_id="O6" value="6.505" spread="6.2944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Whole Body BMD at Week 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 192</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Whole Body BMD at Week 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.923" spread="4.6139"/>
                    <measurement group_id="O2" value="4.295" spread="3.7318"/>
                    <measurement group_id="O3" value="14.797" spread="6.4993"/>
                    <measurement group_id="O4" value="4.549" spread="5.4494"/>
                    <measurement group_id="O5" value="6.086" spread="5.4029"/>
                    <measurement group_id="O6" value="7.223" spread="7.2666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Z-score for Spine BMD at Week 48</title>
        <description>To assess any effect of treatment on growth, Z-scores were used to express the deviation from a reference population for lumbar spine BMD. A Z-score of 0 indicated that a subject was typical of the population for their age, ethnicity, and gender. A negative Z-score indicated that the subject’s recorded value was lower than typical for their age, ethnicity, and gender. A positive Z-score indicates that the subject’s recorded value was higher than typical for their age, ethnicity, and gender. Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 48</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Z-score for Spine BMD at Week 48</title>
          <description>To assess any effect of treatment on growth, Z-scores were used to express the deviation from a reference population for lumbar spine BMD. A Z-score of 0 indicated that a subject was typical of the population for their age, ethnicity, and gender. A negative Z-score indicated that the subject’s recorded value was lower than typical for their age, ethnicity, and gender. A positive Z-score indicates that the subject’s recorded value was higher than typical for their age, ethnicity, and gender. Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.247"/>
                    <measurement group_id="O2" value="-0.10" spread="0.255"/>
                    <measurement group_id="O3" value="0.04" spread="0.393"/>
                    <measurement group_id="O4" value="0.05" spread="0.322"/>
                    <measurement group_id="O5" value="-0.08" spread="0.256"/>
                    <measurement group_id="O6" value="0.05" spread="0.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Z-score for Spine BMD at Week 72</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 72</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Z-score for Spine BMD at Week 72</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.312"/>
                    <measurement group_id="O2" value="-0.05" spread="0.325"/>
                    <measurement group_id="O3" value="0.09" spread="0.498"/>
                    <measurement group_id="O4" value="0.10" spread="0.339"/>
                    <measurement group_id="O5" value="-0.06" spread="0.320"/>
                    <measurement group_id="O6" value="0.10" spread="0.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Z-score for Spine BMD at Week 96</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 96</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Z-score for Spine BMD at Week 96</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.365"/>
                    <measurement group_id="O2" value="-0.07" spread="0.356"/>
                    <measurement group_id="O3" value="-0.02" spread="0.498"/>
                    <measurement group_id="O4" value="-0.13" spread="0.414"/>
                    <measurement group_id="O5" value="-0.10" spread="0.357"/>
                    <measurement group_id="O6" value="-0.11" spread="0.431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Z-score for Spine BMD at Week 144</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 144</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Z-score for Spine BMD at Week 144</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.560"/>
                    <measurement group_id="O2" value="-0.05" spread="0.417"/>
                    <measurement group_id="O3" value="-0.16" spread="0.625"/>
                    <measurement group_id="O4" value="-0.04" spread="0.405"/>
                    <measurement group_id="O5" value="-0.08" spread="0.447"/>
                    <measurement group_id="O6" value="-0.06" spread="0.455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Z-score for Spine BMD at Week 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 192</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Z-score for Spine BMD at Week 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.518"/>
                    <measurement group_id="O2" value="0.08" spread="0.544"/>
                    <measurement group_id="O3" value="-0.26" spread="0.654"/>
                    <measurement group_id="O4" value="-0.05" spread="0.504"/>
                    <measurement group_id="O5" value="0.02" spread="0.548"/>
                    <measurement group_id="O6" value="-0.10" spread="0.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Z-score for Whole Body BMD at Week 48</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 48</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Z-score for Whole Body BMD at Week 48</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.426"/>
                    <measurement group_id="O2" value="-0.15" spread="0.257"/>
                    <measurement group_id="O3" value="0.10" spread="0.370"/>
                    <measurement group_id="O4" value="0.04" spread="0.308"/>
                    <measurement group_id="O5" value="-0.12" spread="0.298"/>
                    <measurement group_id="O6" value="0.05" spread="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Z-score for Whole Body BMD at Week 72</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 72</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Z-score for Whole Body BMD at Week 72</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.398"/>
                    <measurement group_id="O2" value="-0.19" spread="0.338"/>
                    <measurement group_id="O3" value="0.20" spread="0.450"/>
                    <measurement group_id="O4" value="0.06" spread="0.306"/>
                    <measurement group_id="O5" value="-0.16" spread="0.355"/>
                    <measurement group_id="O6" value="0.09" spread="0.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Z-score for Whole Body BMD at Week 96</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 96</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Z-score for Whole Body BMD at Week 96</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.294"/>
                    <measurement group_id="O2" value="-0.19" spread="0.451"/>
                    <measurement group_id="O3" value="0.09" spread="0.528"/>
                    <measurement group_id="O4" value="-0.06" spread="0.432"/>
                    <measurement group_id="O5" value="-0.18" spread="0.424"/>
                    <measurement group_id="O6" value="-0.03" spread="0.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Z-score for Whole Body BMD at Week 144</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 144</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Z-score for Whole Body BMD at Week 144</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.431"/>
                    <measurement group_id="O2" value="-0.21" spread="0.473"/>
                    <measurement group_id="O3" value="-0.06" spread="0.554"/>
                    <measurement group_id="O4" value="-0.16" spread="0.468"/>
                    <measurement group_id="O5" value="-0.22" spread="0.462"/>
                    <measurement group_id="O6" value="-0.14" spread="0.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Z-score for Whole Body BMD at Week 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
        <time_frame>Baseline; Week 192</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Z-score for Whole Body BMD at Week 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis).</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.499"/>
                    <measurement group_id="O2" value="-0.11" spread="0.524"/>
                    <measurement group_id="O3" value="-0.21" spread="0.486"/>
                    <measurement group_id="O4" value="-0.19" spread="0.517"/>
                    <measurement group_id="O5" value="-0.16" spread="0.521"/>
                    <measurement group_id="O6" value="-0.19" spread="0.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Changes in Drug-Resistant Mutations During the Study</title>
        <description>The number of participants with changes in drug-resistant mutations during the study was summarized.</description>
        <time_frame>Baseline through Week 192</time_frame>
        <population>Participants with HBV DNA ≥ 400 copies/mL, with confirmed virologic breakthrough (defined as 2 consecutive increases in HBV DNA of at least 10-fold from nadir, or confirmed values ≥ 400 copies/mL after being &lt; 400 copies/mL while on study medication), or subjects who discontinued early (after Week 24 with HBV DNA ≥ 400 copies/mL) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Changes in Drug-Resistant Mutations During the Study</title>
          <description>The number of participants with changes in drug-resistant mutations during the study was summarized.</description>
          <population>Participants with HBV DNA ≥ 400 copies/mL, with confirmed virologic breakthrough (defined as 2 consecutive increases in HBV DNA of at least 10-fold from nadir, or confirmed values ≥ 400 copies/mL after being &lt; 400 copies/mL while on study medication), or subjects who discontinued early (after Week 24 with HBV DNA ≥ 400 copies/mL) were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>New TDF Drug-Resistant Mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enrichment of TDF Drug-Resistant Mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Loss at Weeks 48, 72, 96, 144, and 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
        <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
        <population>Participants in the Full Analysis Set who were HBeAg-positive at baseline were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Loss at Weeks 48, 72, 96, 144, and 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
          <population>Participants in the Full Analysis Set who were HBeAg-positive at baseline were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="7.7"/>
                    <measurement group_id="O4" value="8.6"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="23.1"/>
                    <measurement group_id="O4" value="11.4"/>
                    <measurement group_id="O5" value="20.8"/>
                    <measurement group_id="O6" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="30.8"/>
                    <measurement group_id="O3" value="38.5"/>
                    <measurement group_id="O4" value="28.6"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="38.5"/>
                    <measurement group_id="O3" value="53.8"/>
                    <measurement group_id="O4" value="34.3"/>
                    <measurement group_id="O5" value="39.6"/>
                    <measurement group_id="O6" value="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="43.6"/>
                    <measurement group_id="O3" value="53.8"/>
                    <measurement group_id="O4" value="37.1"/>
                    <measurement group_id="O5" value="41.7"/>
                    <measurement group_id="O6" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Seroconversion at Weeks 48, 72, 96, 144, and 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
        <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
        <population>Participants in the Full Analysis Set who were HBeAg-positive at baseline were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Seroconversion at Weeks 48, 72, 96, 144, and 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
          <population>Participants in the Full Analysis Set who were HBeAg-positive at baseline were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="15.4"/>
                    <measurement group_id="O3" value="7.7"/>
                    <measurement group_id="O4" value="8.6"/>
                    <measurement group_id="O5" value="14.6"/>
                    <measurement group_id="O6" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="23.1"/>
                    <measurement group_id="O4" value="11.4"/>
                    <measurement group_id="O5" value="20.8"/>
                    <measurement group_id="O6" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="30.8"/>
                    <measurement group_id="O3" value="38.5"/>
                    <measurement group_id="O4" value="25.7"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="38.5"/>
                    <measurement group_id="O3" value="53.8"/>
                    <measurement group_id="O4" value="34.3"/>
                    <measurement group_id="O5" value="37.5"/>
                    <measurement group_id="O6" value="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="38.5"/>
                    <measurement group_id="O3" value="53.8"/>
                    <measurement group_id="O4" value="37.1"/>
                    <measurement group_id="O5" value="37.5"/>
                    <measurement group_id="O6" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were HBeAg-Positive at Baseline Who Had HBV DNA &lt; 400 Copies/mL, Normal ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
        <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
        <population>Participants in the Full Analysis Set who were HBeAg-positive at baseline were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were HBeAg-Positive at Baseline Who Had HBV DNA &lt; 400 Copies/mL, Normal ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
          <population>Participants in the Full Analysis Set who were HBeAg-positive at baseline were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="12.8"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="12.5"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="15.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="14.6"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="28.2"/>
                    <measurement group_id="O3" value="30.8"/>
                    <measurement group_id="O4" value="22.9"/>
                    <measurement group_id="O5" value="31.3"/>
                    <measurement group_id="O6" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="30.8"/>
                    <measurement group_id="O3" value="46.2"/>
                    <measurement group_id="O4" value="25.7"/>
                    <measurement group_id="O5" value="29.2"/>
                    <measurement group_id="O6" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="28.2"/>
                    <measurement group_id="O3" value="46.2"/>
                    <measurement group_id="O4" value="25.7"/>
                    <measurement group_id="O5" value="29.2"/>
                    <measurement group_id="O6" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Abnormal ALT at Baseline Who Had Normalized ALT at Weeks 48, 72, 96, 144, and 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
        <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
        <population>Participants in the Full Analysis Set with abnormal ALT at baseline were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Abnormal ALT at Baseline Who Had Normalized ALT at Weeks 48, 72, 96, 144, and 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
          <population>Participants in the Full Analysis Set with abnormal ALT at baseline were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="21.2"/>
                    <measurement group_id="O5" value="74.3"/>
                    <measurement group_id="O6" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="74.3"/>
                    <measurement group_id="O6" value="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="78.6"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="63.6"/>
                    <measurement group_id="O5" value="80.0"/>
                    <measurement group_id="O6" value="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="72.7"/>
                    <measurement group_id="O5" value="68.6"/>
                    <measurement group_id="O6" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="77.8"/>
                    <measurement group_id="O4" value="69.7"/>
                    <measurement group_id="O5" value="77.1"/>
                    <measurement group_id="O6" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Abnormal ALT at Baseline Who Had HBV DNA &lt; 400 Copies/mL and Normalized ALT at Weeks 48, 72, 96, 144, and 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
        <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
        <population>Participants in the Full Analysis Set with abnormal ALT at baseline were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Abnormal ALT at Baseline Who Had HBV DNA &lt; 400 Copies/mL and Normalized ALT at Weeks 48, 72, 96, 144, and 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
          <population>Participants in the Full Analysis Set with abnormal ALT at baseline were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="74.3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="74.3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="78.6"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="54.5"/>
                    <measurement group_id="O5" value="80.0"/>
                    <measurement group_id="O6" value="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="69.7"/>
                    <measurement group_id="O5" value="68.6"/>
                    <measurement group_id="O6" value="69.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="67.9"/>
                    <measurement group_id="O3" value="77.8"/>
                    <measurement group_id="O4" value="57.6"/>
                    <measurement group_id="O5" value="71.4"/>
                    <measurement group_id="O6" value="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were HBeAg-Positive With Abnormal ALT at Baseline Who Had HBV DNA &lt; 400 Copies/mL, Normalized ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192</title>
        <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
        <time_frame>Baseline; Weeks 48, 72, 96, 144, and 192</time_frame>
        <population>Participants in the Full Analysis Set who were HBeAg-Positive with abnormal ALT at baseline were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 12-14 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O2">
            <title>TDF 15-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O3">
            <title>Placebo 12-14 Years</title>
            <description>TDF placebo tablet once daily in participants 12-14 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo 15-17 Years</title>
            <description>TDF placebo tablet once daily in participants 15-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O5">
            <title>Total TDF 12-17 Years</title>
            <description>TDF 300 mg tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
          <group group_id="O6">
            <title>Total Placebo 12-17 Years</title>
            <description>TDF placebo tablet once daily in participants 12-17 years of age in the Randomized Phase, followed by TDF 300 mg tablet once daily in the Open-Label Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were HBeAg-Positive With Abnormal ALT at Baseline Who Had HBV DNA &lt; 400 Copies/mL, Normalized ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192</title>
          <description>Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.</description>
          <population>Participants in the Full Analysis Set who were HBeAg-Positive with abnormal ALT at baseline were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="18.5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="18.2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="22.2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="21.2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="24.2"/>
                    <measurement group_id="O5" value="36.4"/>
                    <measurement group_id="O6" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="29.6"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="27.3"/>
                    <measurement group_id="O5" value="30.3"/>
                    <measurement group_id="O6" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="29.6"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="27.3"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through end of the Open-Label Phase (up to 4 years)</time_frame>
      <desc>Safety Analysis Set</desc>
      <group_list>
        <group group_id="E1">
          <title>Double-Blind TDF</title>
          <description>Adverse events reported in this group occurred during the Randomized Phase (+7 days for participants who did not continue to the Open-Label Phase) and includes all participants who received double-blind TDF during the Randomized Phase of the study.</description>
        </group>
        <group group_id="E2">
          <title>Double-Blind Placebo</title>
          <description>Adverse events reported in this group occurred during the Randomized Phase (+7 days for participants who did not continue to the Open-Label Phase) and includes all participants who received placebo during the Randomized Phase of the study.</description>
        </group>
        <group group_id="E3">
          <title>Open-Label TDF-TDF</title>
          <description>Adverse events reported in this group occurred during the Open-Label Phase and includes all participants who received double-blind TDF during the Randomized Phase of the study and continued to the Open-Label Phase.</description>
        </group>
        <group group_id="E4">
          <title>Open-Label Placebo-TDF</title>
          <description>Adverse events reported in this group occurred during the Open-Label Phase and includes all participants who received placebo during the Randomized Phase of the study and continued to the Open-Label Phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosures</name_or_title>
      <organization>Gilead Sciences</organization>
      <email>ClinicalTrialDisclosures@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

